Overton Sidesteps Policy Questions as Novo Nordisk Bets $1.3 Billion on Long-Acting Injections
By Ed Silverman · STAT News · 2026-09-25

According to STAT News, FDA commissioner nominee Heidi Overton maintained a neutral stance during her Senate confirmation hearing, avoiding specific commitments on controversial regulatory topics. Meanwhile, Novo Nordisk is investing heavily in Nanexa’s PharmaShell delivery syste
According to STAT News, FDA commissioner nominee Heidi Overton maintained a neutral stance during her Senate confirmation hearing, avoiding specific commitments on controversial regulatory topics. Meanwhile, Novo Nordisk is investing heavily in Nanexa’s PharmaShell delivery syste